National Jewish Health
- Type
- Teaching hospital
- Where
- Denver, CO
- Medicare CCN
- 060107
- Received
- $6,208,844 in 321 records, 2023 ($2,665,886 general, $3,542,958 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: National Jewish Health Fuzzy (name and state)
- Business registration: National Jewish Health Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Business registration: National Jewish Health Company Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH, INC. Fuzzy (name and state)
- Nonprofit contractor: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Plan sponsor: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Federal award recipient: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Nonprofit: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Patent assignee: National Jewish Health Fuzzy (name and state)
- Trademark owner: National Jewish Health Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 95 | $2,665,886 |
| 2023 | Research payment | 226 | $3,542,958 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 226 | $3,542,958 |
| Grant | 16 | $2,263,525 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 30 | $277,702 |
| Space rental or facility fees (teaching hospital only) | 14 | $48,500 |
| Royalty or License | 26 | $45,894 |
| Gift | 1 | $15,000 |
| Education | 3 | $8,500 |
| Food and Beverage | 2 | $6,000 |
| Debt forgiveness | 1 | $510 |
| Consulting Fee | 1 | $210 |
| Honoraria | 1 | $44 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Merck Sharp & Dohme LLC | $11,084 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $510 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-12-27 | United Therapeutics Corporation | $11,254 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-27 | United Therapeutics Corporation | $3,500 | Education | Cash or cash equivalent | 2023 | ||
| 2023-12-25 | AstraZeneca Pharmaceuticals LP | $7,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-12-21 | Apellis Pharmaceuticals, Inc. | $12,685 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-12-21 | Apellis Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-12-20 | Insmed, Inc. | $1,633 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-12-20 | Insmed, Inc. | $1,217 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-12-20 | Insmed, Inc. | $1,098 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-12-20 | Insmed, Inc. | $1,098 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-12-20 | Insmed, Inc. | $629 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-12-20 | Insmed, Inc. | $59 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-12-20 | Insmed, Inc. | $59 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-12-19 | Electromed, Inc. | $3,500 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2023 | |
| 2023-12-19 | Regeneron Pharmaceuticals, Inc. | $280 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $11,737 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2023 | |
| 2023-12-18 | Apellis Pharmaceuticals, Inc. | $6,752 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Apellis Pharmaceuticals, Inc. | $5,748 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Janssen Research & Development, LLC | $3,692 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2023 | |
| 2023-12-18 | Fisher Scientific Company L.L.C. | $210 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-14 | Alexion Pharmaceuticals, Inc. | $23,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-12-14 | Alexion Pharmaceuticals, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-12-12 | United Therapeutics Corporation | $5,692 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-12 | United Therapeutics Corporation | $3,500 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-12 | Regeneron Pharmaceuticals, Inc. | $280 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-12-08 | Life Technologies Corporation | $20,660 | Royalty or License (17 payments) | Cash or cash equivalent | Monoclonal Antibodies Device, Mouse Hybridoma Cell Line | 2023 | |
| 2023-12-08 | Regeneron Pharmaceuticals, Inc. | $224 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-12-06 | GlaxoSmithKline, LLC. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-12-04 | AstraZeneca Pharmaceuticals LP | $130,500 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2023 | |
| 2023-12-01 | Amgen Inc. | $1,250 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-12-01 | Amgen Inc. | $1,250 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-11-29 | Apellis Pharmaceuticals, Inc. | $20,000 | Research payment | Cash or cash equivalent | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex | 2023 | |
| 2023-11-29 | Apellis Pharmaceuticals, Inc. | $1,575 | Research payment | Cash or cash equivalent | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2023 | |
| 2023-11-29 | Apellis Pharmaceuticals, Inc. | $784 | Research payment | Cash or cash equivalent | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | 2023 | |
| 2023-11-28 | AstraZeneca Pharmaceuticals LP | $126,483 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-11-28 | Regeneron Pharmaceuticals, Inc. | $336 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-11-23 | Alexion Pharmaceuticals, Inc. | $14,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-11-23 | Alexion Pharmaceuticals, Inc. | $5,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-11-23 | Alexion Pharmaceuticals, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-11-22 | Regeneron Healthcare Solutions, Inc. | $47,500 | Grant | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2023 | |
| 2023-11-21 | Regeneron Pharmaceuticals, Inc. | $224 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-11-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $33,040 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | CT scans using deep learning to assess lung fibros | 2023 |
| 2023-11-20 | AstraZeneca Pharmaceuticals LP | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FASENRA Biological, Respiratory | 2023 | |
| 2023-11-17 | Regeneron Pharmaceuticals, Inc. | $1,232 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-11-17 | Becton, Dickinson and Company | $534 | Royalty or License | Cash or cash equivalent | Horizon Device, Reagents | 2023 | |
| 2023-11-17 | Becton, Dickinson and Company | $153 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-11-17 | Becton, Dickinson and Company | $148 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-11-17 | Becton, Dickinson and Company | $38 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-11-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-11-13 | CSL Behring | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-11-10 | Apellis Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-11-07 | Paratek Pharmaceuticals, Inc. | $24,309 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe | 2023 |
| 2023-11-07 | Paratek Pharmaceuticals, Inc. | $19,856 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | MIC Testing on Retrospectively Collected Isolates | 2023 |
| 2023-11-07 | United Therapeutics Corporation | $4,758 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-11-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2023 | |
| 2023-10-31 | Paratek Pharmaceuticals, Inc. | $16,738 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe | 2023 |
| 2023-10-31 | Beckman Coulter, Inc. | $10,000 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-10-27 | Insmed, Inc. | $2,926 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-10-27 | Insmed, Inc. | $1,862 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcom | 2023 |
| 2023-10-26 | Apellis Pharmaceuticals, Inc. | $24,850 | Research payment | Cash or cash equivalent | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | 2023 | |
| 2023-10-26 | Apellis Pharmaceuticals, Inc. | $8,500 | Research payment | Cash or cash equivalent | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex | 2023 | |
| 2023-10-26 | Novartis Pharmaceuticals Corporation | $6,131 | Research payment | Cash or cash equivalent | A 52 week multicenter randomized double blind placebocontrolled study to assess the efficacy and safety of QAW039 when a | 2023 | |
| 2023-10-26 | Apellis Pharmaceuticals, Inc. | $2,250 | Research payment | Cash or cash equivalent | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | 2023 | |
| 2023-10-26 | Apellis Pharmaceuticals, Inc. | $900 | Research payment | Cash or cash equivalent | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2023 | |
| 2023-10-26 | Apellis Pharmaceuticals, Inc. | $185 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-10-25 | Regeneron Pharmaceuticals, Inc. | $3,221 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-10-25 | Regeneron Pharmaceuticals, Inc. | $336 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-10-22 | AstraZeneca Pharmaceuticals LP | $15,000 | Gift | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2023 | |
| 2023-10-20 | SANOFI US SERVICES INC. | $2,800 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patient | 2023 |
| 2023-10-19 | Alexion Pharmaceuticals, Inc. | $30,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-19 | Janssen Research & Development, LLC | $4,533 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2023 | |
| 2023-10-19 | Alexion Pharmaceuticals, Inc. | $1,740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-17 | United Therapeutics Corporation | $14,057 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-10-17 | United Therapeutics Corporation | $10,201 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-10-17 | Genentech, Inc. | $4,000 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | 1LM SCLC Tecentriq Lurbinectedin | 2023 |
| 2023-10-17 | AstraZeneca Pharmaceuticals LP | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-12 | Genentech, Inc. | $294 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | Measuring Responses to Xolair Omalizumab using mHealth Technologies | 2023 |
| 2023-10-10 | GENZYME CORPORATION | $961,330 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie | 2023 |
| 2023-10-10 | Regeneron Pharmaceuticals, Inc. | $112 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-10-06 | Apellis Pharmaceuticals, Inc. | $8,250 | Research payment | Cash or cash equivalent | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex | 2023 | |
| 2023-10-03 | Regeneron Pharmaceuticals, Inc. | $448 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-10-03 | Regeneron Pharmaceuticals, Inc. | $336 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-10-02 | AstraZeneca Pharmaceuticals LP | $7,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-02 | Insmed, Inc. | $1,656 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-02 | Insmed, Inc. | $1,610 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-02 | Insmed, Inc. | $1,574 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-02 | Insmed, Inc. | $629 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-02 | Insmed, Inc. | $629 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-02 | Insmed, Inc. | $83 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-02 | Insmed, Inc. | $83 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-02 | Insmed, Inc. | $30 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-02 | Insmed, Inc. | $29 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 |
| 2023-10-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2023 | |
| 2023-09-28 | Apellis Pharmaceuticals, Inc. | $13,209 | Research payment | Cash or cash equivalent | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | 2023 | |
| 2023-09-28 | Apellis Pharmaceuticals, Inc. | $9,500 | Research payment | Cash or cash equivalent | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex | 2023 | |
| 2023-09-28 | Apellis Pharmaceuticals, Inc. | $7,100 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-09-28 | Alexion Pharmaceuticals, Inc. | $4,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-09-28 | Apellis Pharmaceuticals, Inc. | $900 | Research payment | Cash or cash equivalent | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2023 | |
| 2023-09-28 | Apellis Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-09-28 | Apellis Pharmaceuticals, Inc. | $250 | Research payment | Cash or cash equivalent | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | 2023 | |
| 2023-09-21 | Alexion Pharmaceuticals, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-09-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $74,948 | Research payment | Cash or cash equivalent | PDE4 Phase III trial in PF ILD | 2023 | |
| 2023-09-18 | Genentech, Inc. | $2,103 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | Measuring Responses to Xolair Omalizumab using mHealth Technologies | 2023 |
| 2023-09-18 | Genentech, Inc. | $1,357 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | Measuring Responses to Xolair Omalizumab using mHealth Technologies | 2023 |
| 2023-09-14 | Alexion Pharmaceuticals, Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-09-12 | Genentech USA, Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xolair Biological, Immunology | 2023 | |
| 2023-09-12 | Regeneron Pharmaceuticals, Inc. | $336 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-09-07 | SANOFI US SERVICES INC. | $3,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patient | 2023 |
| 2023-09-06 | United Therapeutics Corporation | $7,028 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-09-06 | United Therapeutics Corporation | $1,025 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-09-06 | Regeneron Pharmaceuticals, Inc. | $224 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-09-05 | Bayer Healthcare Pharmaceuticals Inc. | $20,000 | Research payment | Cash or cash equivalent | PHAB 3.0 Award Agreement | 2023 | |
| 2023-09-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2023 | |
| 2023-09-01 | Allerderm Laboratories | $17,416 | Research payment | Cash or cash equivalent | Metal Allergen Safety and Efficacy | 2023 | |
| 2023-09-01 | Alexion Pharmaceuticals, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-09-01 | Regeneron Pharmaceuticals, Inc. | $336 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-08-30 | Apellis Pharmaceuticals, Inc. | $11,190 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-08-30 | Apellis Pharmaceuticals, Inc. | $6,773 | Research payment | Cash or cash equivalent | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | 2023 | |
| 2023-08-30 | Apellis Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-08-29 | Paratek Pharmaceuticals, Inc. | $32,983 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe | 2023 |
| 2023-08-25 | Janssen Research & Development, LLC | $1,739 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2023 | |
| 2023-08-24 | Alexion Pharmaceuticals, Inc. | $3,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-08-24 | Alexion Pharmaceuticals, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-08-24 | Becton, Dickinson and Company | $333 | Royalty or License | Cash or cash equivalent | Horizon Device, Reagents | 2023 | |
| 2023-08-24 | Becton, Dickinson and Company | $250 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-08-24 | Becton, Dickinson and Company | $31 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-08-24 | Becton, Dickinson and Company | $13 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-08-24 | Becton, Dickinson and Company | $8 | Royalty or License | Cash or cash equivalent | 2023 | ||
| 2023-08-23 | Regeneron Pharmaceuticals, Inc. | $5,518 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-08-18 | AstraZeneca Pharmaceuticals LP | $199,267 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-08-15 | Roche Products Limited | $1,880 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | Ph III OLE Trial to Evaluate Long term Safety and Efficacy of PRM 151 in Patients with IPF | 2023 |
| 2023-08-14 | Roche Products Limited | $1,005 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-08-14 | Roche Products Limited | $1,005 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-08-08 | Paratek Pharmaceuticals, Inc. | $10,328 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe | 2023 |
| 2023-08-08 | EMD Millipore Corporation | $2,500 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2023 | |
| 2023-08-04 | Apellis Pharmaceuticals, Inc. | $31,110 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-08-04 | Apellis Pharmaceuticals, Inc. | $6,000 | Research payment | Cash or cash equivalent | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex | 2023 | |
| 2023-08-04 | Apellis Pharmaceuticals, Inc. | $1,350 | Research payment | Cash or cash equivalent | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2023 | |
| 2023-08-03 | Janssen Research & Development, LLC | $39,766 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co | 2023 | |
| 2023-08-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2023 | |
| 2023-08-01 | Genentech, Inc. | $2,500 | Research payment | Cash or cash equivalent | Ph IIb of Astegolimab in COPD | 2023 | |
| 2023-08-01 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Ph IIb of Astegolimab in COPD | 2023 | |
| 2023-07-31 | Janssen Research & Development, LLC | $5,658 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2023 | |
| 2023-07-27 | Alexion Pharmaceuticals, Inc. | $28,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-07-27 | Genentech, Inc. | $2,975 | Research payment | Cash or cash equivalent | Ph IIb of Astegolimab in COPD | 2023 | |
| 2023-07-27 | Alexion Pharmaceuticals, Inc. | $672 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-07-26 | United Therapeutics Corporation | $41,174 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA | 2023 | |
| 2023-07-26 | Merck Sharp & Dohme LLC | $5,056 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2023 |
| 2023-07-25 | Paratek Pharmaceuticals, Inc. | $19,461 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe | 2023 |
| 2023-07-25 | United Therapeutics Corporation | $2,052 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-07-19 | Genentech, Inc. | $7,000 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | 1LM SCLC Tecentriq Lurbinectedin | 2023 |
| 2023-07-19 | Luminex Corporation | $44 | Honoraria | In-kind items and services | ARIES Device, Device | 2023 | |
| 2023-07-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $93,249 | Research payment | Cash or cash equivalent | PDE4 Phase III trial in IPF patients | 2023 | |
| 2023-07-13 | SANOFI US SERVICES INC. | $3,400 | Research payment | Cash or cash equivalent | Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Sm | 2023 | |
| 2023-07-13 | SANOFI US SERVICES INC. | $2,666 | Research payment | Cash or cash equivalent | Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Sm | 2023 | |
| 2023-07-11 | United Therapeutics Corporation | $6,282 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-07-04 | Regeneron Pharmaceuticals, Inc. | $336 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-07-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2023 | |
| 2023-06-29 | Apellis Pharmaceuticals, Inc. | $31,915 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-06-29 | Alexion Pharmaceuticals, Inc. | $5,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-29 | Apellis Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-06-29 | Alexion Pharmaceuticals, Inc. | $435 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-28 | Novartis Pharmaceuticals Corporation | $273,830 | Grant | In-kind items and services | 2023 | ||
| 2023-06-28 | Regeneron Pharmaceuticals, Inc. | $336 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-06-26 | Insmed, Inc. | $2,432 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $1,691 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $1,662 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $1,633 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $1,574 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $1,415 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $1,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcom | 2023 |
| 2023-06-26 | Insmed, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $1,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcom | 2023 |
| 2023-06-26 | Insmed, Inc. | $1,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-06-26 | Insmed, Inc. | $1,000 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-06-26 | Insmed, Inc. | $629 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $629 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $629 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $500 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcom | 2023 |
| 2023-06-26 | Insmed, Inc. | $500 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-06-26 | Insmed, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $300 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2023 | |
| 2023-06-26 | Insmed, Inc. | $287 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-06-26 | Genentech, Inc. | $223 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | Neoadjuvant NSCLC | 2023 |
| 2023-06-22 | Novartis Pharmaceuticals Corporation | $172,650 | Grant | In-kind items and services | 2023 | ||
| 2023-06-20 | Regeneron Pharmaceuticals, Inc. | $336 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-06-14 | GENZYME CORPORATION | $376 | Research payment | Cash or cash equivalent | NEXVIAZYME Biological, Genetic Disease | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ | 2023 |
| 2023-06-13 | Regeneron Pharmaceuticals, Inc. | $392 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
| 2023-06-12 | PFIZER INC. | $30,013 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | WI206744 2015 ASPIRE US CHANGE IN SERUM AND SPUTUM BIOMARKERS OVER TIME IN THE DEVELOPMENT OF RHEUMATOID ARTHRITISASSOCI | 2023 |
| 2023-06-06 | Paratek Pharmaceuticals, Inc. | $11,784 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safe | 2023 |
| 2023-06-06 | Roche Products Limited | $4,242 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | Ph III OLE Trial to Evaluate Long term Safety and Efficacy of PRM 151 in Patients with IPF | 2023 |
| 2023-06-02 | Apellis Pharmaceuticals, Inc. | $61,775 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-06-02 | Apellis Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-06-01 | SANOFI US SERVICES INC. | $61,947 | Research payment | Cash or cash equivalent | REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | 2023 | |
| 2023-05-25 | Alexion Pharmaceuticals, Inc. | $28,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-05-25 | Alexion Pharmaceuticals, Inc. | $15,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-05-24 | Regeneron Pharmaceuticals, Inc. | $1,232 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2023 |
The latest 200 records of 321.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Denver, CO, county Denver County, CO, state Colorado; placed by its city name.
| Measure | Place (city or town) Denver, CO | County Denver County, CO | State Colorado |
|---|---|---|---|
| Population B01003 | 718,877 | 718,877 | 5,862,189 |
| Population, 2020 census P1 | 715,522 | 715,522 | 5,773,714 |
| Median age B01002 | 35.3 | 35.3 | 37.7 |
| Under 18 B01001 | 18.0% | 18.0% | 21.0% |
| 65 and over B01001 | 12.5% | 12.5% | 15.6% |
| Households B11001 | 335,428 | 335,428 | 2,374,218 |
| Foreign born B05002 | 14.5% | 14.5% | 9.8% |
| Median household income B19013 | $94,718 | $94,718 | $95,470 |
| Median family income B19113 | $124,743 | $124,743 | $119,139 |
| Per capita income B19301 | $64,163 | $64,163 | $52,636 |
| Poverty rate B17001 | 11.2% | 11.2% | 9.4% |
| Unemployment rate B23025 | 4.9% | 4.9% | 4.6% |
| Civilian labor force B23025 | 447,681 | 447,681 | 3,235,476 |
| Mean commute (minutes) B08013 | 24.9 | 24.9 | 25.2 |
| Bachelor's degree or higher B15003 | 56.5% | 56.5% | 45.7% |
| Housing units B25001 | 359,581 | 359,581 | 2,589,053 |
| Owner-occupied B25003 | 48.8% | 48.8% | 66.2% |
| Renters B25003 | 51.2% | 51.2% | 33.8% |
| Median home value B25077 | $616,000 | $616,000 | $539,400 |
| Median gross rent B25064 | $1,831 | $1,831 | $1,761 |
| White, not Hispanic B03002 | 54.0% | 54.0% | 64.8% |
| Black B03002 | 8.6% | 8.6% | 3.8% |
| Hispanic or Latino B03002 | 28.0% | 28.0% | 22.5% |
| Asian B03002 | 3.6% | 3.6% | 3.2% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.4% |
Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, CO.
Comments